Exosome-based cancer Dx attracts $20m investment
This article was originally published in Clinica
Exosome Diagnostics has raised $20m in its first institutional financing round. Co-lead investors were NGN Capital and Forbion Capital Partners. Exosome, which is based in New York and Munich, said it will use the funds to further develop and commercialise a series of body fluid-based cancer diagnostics through its proprietary, exosome-based technology platform. Exosomes are lipid-covered microvesicles shed by solid tumours into bodily fluids, such as blood and urine. These microvesicles contain large sequences of a tumour’s genetic material in an enriched form. The company has demonstrated that it is able to extract high-quality exosomes from the blood and urine of cancer patients; and then detect, with high sensitivity and specificity, key genes and gene mutations associated with a variety of cancers.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.